FindTrial
Sign In

Introduction of steroid drugs in liver transplant as immunnotherapy, High dose versus low dose: A Comparative Retrospective Study (HILTS Study)

High Versus Low Dose Corticosteroid Induction in Liver Transplantation: A Comparative Retrospective Study - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/06/112978
Enrollment
170
Registered
2026-06-18
Start date
Unknown
Completion date
Unknown
Last updated
2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K769- Liver disease, unspecified

Interventions

Intervention1: Nil: Nil

Sponsors

Aster CMI Hospital
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Adult patients ( greater or equal to 18 years) undergoing liver transplantation 2 Transplants performed between January 2023 and June 2025 3 Patients receiving corticosteroid induction therapy 4 Availability of discharge and follow-up data

Exclusion criteria

Exclusion criteria: 1 Pediatric liver transplant recipients 2 Multi-organ transplant recipients 3 Patients with incomplete immunosuppression or outcome data

Design outcomes

Primary

MeasureTime frame
Incidence of acute cellular rejection ACR. High-dose steroid induction (greater or equal to 500 mg methylprednisolone) Low-dose steroid induction (less than 500 mg methylprednisolone)Timepoint: 1 month and 3 months—

Secondary

MeasureTime frame
Incidence of sepsis within 1 month post-transplant,Type of infection (urosepsis, pneumonia, others), Centre-wise differences in induction steroid practice, relationship of steroids with MELD score and etiology of Liver diseaseTimepoint: 1 month and 3 months—

Countries

India

Contacts

Public ContactDr Sonal Asthana

Aster CMI

drsonal.asthana@asterhospital.in09686976379

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Jun 29, 2026